Role of Indicator Test (Neuropad) in Detecting Diabetic Neuropathy
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Neuropad Test for Detection of Sudomotor Dysfunction in Patients With Painful and Painless Diabetic Neuropathy and Charcot Neuroarthropathy|
- Identify patients with peripheral neuropathy with the Neuropad indicator test [ Time Frame: 6 months ] [ Designated as safety issue: No ]
|Study Start Date:||July 2009|
|Study Completion Date:||June 2013|
|Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
Diabetic patients without neuropathy
Diabetic patients with painless neuropathy
Diabetic patients with painful neuropathy
Diabetic patients with Charcot neuroarthropathy
Control non-diabetic subjects
With increasing nervous dysfunction, the function of the sweat glands in the feet also diminishes and can cease completely. As a result the skin becomes brittle and dry, making it more susceptible to fissuring and breakdown leading to foot ulceration. This is where the diagnosis using the Neuropad plaster might be useful. The Neuropad measures sweat production and have been proposed as a new test of neuropathy (8,9). The Neuropad examines the function of the sweat glands by means of a colour indicator. The indicator test enables the diagnosis of neuropathy in a substantial proportion of patients with normal clinical examination (10).
This colour indicator, a cobalt-II-salt, is applied in the form of a plaster to the area of skin on the patient's foot to be examined. In healthy subjects, the moisture (sweat) on the foot changes the colour of the Neuropad plaster from blue to pink normally within minutes. However, if the colour does not change completely or very slowly, this indicates initial nerve damage. This test is, as yet, the only one that examines changes in moistness of the foot. The speed and scale of the colour change of the Neuropad plaster can then be assessed as indicators of sudomotor function and thus as indicators of diabetic neuropathy as well. Although the test has been done in patients with diabetic neuropathy it has not been used as a discriminator in painless and painful neuropathy, or in patients with Charcot neuroarthropathy.
In this study we aim to assess the presence of sudomotor dysfunction in patients with painful and painless neuropathy and patients with Charcot foot.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00895440
|Tameside General Hospital|
|Ashton-under-Lyne, Lancashire, United Kingdom, OL69RW|
|Principal Investigator:||Edward Jude, MD, MRCP||Tameside General Hospital|